Third Circuit rescues Fresenius Kabi’s monopolisation claims against Par
An appellate court has revived drug manufacturer Fresenius Kabi’s antitrust lawsuit against Par Pharmaceutical, determining that a lower court in New Jersey failed to conduct a requisite analysis of the issues in the case.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10